Additionally, the NPD-post group exhibited a greater inclination towards antigen presentation, oxidative stress, and cell death compared to the NPD-pre group, indicating the strong tumor-killing ability of anti-PD-1 therapy. The gene discussed is PDCD1; the disease is neoplasm.